ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth

A significant proportion of breast cancers are driven by ErbB2/Her2 oncoprotein that they overexpress. These malignancies are typically treated with various ErbB2-targeted drugs, but many such cancers develop resistance to these agents and become incurable. Conceivably, treatment of ErbB2-positive c...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoyang, Chipurupalli, Sandhya, Jiang, Peijia, Tavasoli, Mahtab, Yoo, Byong Hoon, McPhee, Michael, Mazinani, Sina, Francia, Giulio, Kerbel, Robert S., Rosen, Kirill V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357009/
https://www.ncbi.nlm.nih.gov/pubmed/35933456
http://dx.doi.org/10.1038/s41419-022-05117-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357009/
https://www.ncbi.nlm.nih.gov/pubmed/35933456
http://dx.doi.org/10.1038/s41419-022-05117-9

Ejemplares similares